| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Adeoye Y Olukotun is Director at ARWR, with reported holdings spanning 2 companies. Adeoye Y Olukotun's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.9M at current prices.
Our model assigns Adeoye Y Olukotun a middling insider score of 52/100, based on 6 past trades. Over a 12-month horizon, 40.0% of those trades were profitable, with an average 12-month return of -24.5%.
Adeoye Y Olukotun's largest disclosed position is in ARWR as Director, worth about $1.9M. The ARWR filings lean toward selling, a net 36,209 shares.
Adeoye Y Olukotun has 24 Form 4 filings on record from September 2018 to August 2026, across 2 companies: Director at Arrowhead Pharmaceuticals (ARWR), 2021–2026; Director at Tonix Pharmaceuticals (TNXP), 2018–2026.
The 30 reported transactions were 12 open-market sales, 10 option or other derivative awards, 6 stock awards and 1 other transaction, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $5K and 7 sales worth about $1.9M.
The only open-market purchase was 5,350 shares of TNXP at an average $0.94 on August 13, 2020, about $5K.
The largest open-market sale was 10,000 shares of ARWR at an average $67.66 on December 19, 2025, about $677K.
3 of the 4 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other was not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 2,000 | $86.96 | $173,920.00 | -6.0% | - | - | |
| Dec 19, 2025 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell10b5-1 | 10,000 | $67.66 | $676,623.28 | -22.9% | -16.4% | - | |
| Jan 23, 2025 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell10b5-1 | 959 | $21.00 | $20,139.00 | -2.6% | -39.6% | +211.4% | |
| Dec 27, 2024 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell10b5-1 | 2,850 | $20.00 | $57,000.00 | -7.2% | -27.2% | +270.0% | |
| Mar 3, 2023 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 11,350 | $32.65 | $370,577.50 | -59.1% | +7.2% | +11.5% | |
| Jan 3, 2022 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 4,050 | $64.75 | $262,233.04 | -45.0% | -27.7% | -45.0% | |
| Sep 13, 2021 | ARWR Arrowhead Pharmaceuticals, Inc. | Director | Sell | 5,000 | $63.76 | $318,800.00 | -35.7% | +11.0% | -44.3% | |
| Aug 13, 2020 | TNXP Tonix Pharmaceuticals Holding Corp. | Director | Buy | 5,350 | $0.94 | $5,029.00 | New | - | - |